does pfizer have a glp 1 drug Phase IIb Data Support Monthly GLP-1 Dosing for Obesity Pfizer dips on new data
Description
Microneedle systems may eventually solve part of this problem
In the SUSTAIN-6 study, which compared subcutaneous semaglutide to placebo, DR complications occurred in 3% of semaglutide and 1.8% of placebo subjects
15, eadh4453 (2023)
Finally, publication bias cannot be excluded, especially given the increasing clinical interest in GLP-1RAs and the greater likelihood of publishing studies with favorable outcomes
